AF
RNTX

Allworth Financial’s Rein Therapeutics RNTX Stock Holding History

Allworth Financial’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25
Closed -$1K – 2149
2021
Q3 		$1K Hold
25
– – ﹤0.01% 1815
2021
Q2 		$1K Hold
25
– – ﹤0.01% 1512
2021
Q1 		$1K Hold
25
– – ﹤0.01% 1443
2020
Q4 		$1K Hold
25
– – ﹤0.01% 1309
2020
Q3 		$1K Hold
25
– – ﹤0.01% 1142
2020
Q2 		$1K Buy
+25
New +$407 ﹤0.01% 1142

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Allworth Financial's RNTX Position: Q4 2021 in Review

Allworth Financial sold out of Rein Therapeutics (RNTX) in Q4 2021, closing a stake of 25 shares — an estimated $1K sold.

Allworth Financial first reported a position in RNTX in Q2 2020 and held it in 6 quarters. The position peaked at $1K in Q3 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q4 2021.

  • Allworth Financial reported no remaining Rein Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Allworth Financial sold 25 Rein Therapeutics shares in Q4 2021, an estimated $1K.
  • Allworth Financial first reported a position in Rein Therapeutics in Q2 2020 and held it in 6 quarters.
  • Allworth Financial's Rein Therapeutics position peaked at $1K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2021.

Based on Allworth Financial's 13F filing for Q4 2021, filed 21 Jan 2022.